Pharmacotherapy of alzheimer’s disease: seeking clarity in a time of uncertainty

Ibrahim, Nurul Husna and Yahaya, Mohamad Fairuz and Mohamed, Wael Mohamed Yousef and Seong, Ling Teoh and Chua, Kien Hui and Kumar, Jaya (2020) Pharmacotherapy of alzheimer’s disease: seeking clarity in a time of uncertainty. Frontiers in Pharmacology, 11. pp. 1-16. ISSN 1663-9812

	PDF - Published Version Restricted to Repository staff only Download (2MB) | Request a copy
	PDF (SCOPUS) - Supplemental Material Restricted to Repository staff only Download (255kB) | Request a copy
	PDF (WoS) - Supplemental Material Restricted to Repository staff only Download (679kB) | Request a copy

Abstract

Alzheimer’s disease (AD) is recognized as a major health hazard that mostly affects people older than 60 years. AD is one of the biggest medical, economic, and social concerns to patients and their caregivers. AD was ranked as the 5th leading cause of global deaths in 2016 by the World Health Organization (WHO). Many drugs targeting the production, aggregation, and clearance of Aβ plaques failed to give any conclusive clinical outcomes. This mainly stems from the fact that AD is not a disease attributed to a single-gene mutation. Two hallmarks of AD, Aβ plaques and neurofibrillary tangles (NFTs), can simultaneously induce other AD etiologies where every pathway is a loop of consequential events. Therefore, the focus of recent AD research has shifted to exploring other etiologies, such as neuroinflammation and central hyperexcitability. Neuroinflammation results from the hyperactivation of microglia and astrocytes that release pro-inflammatory cytokines due to the neurological insults caused by Aβ plaques and NFTs, eventually leading to synaptic dysfunction and neuronal death. This review will report the failures and side effects of many anti-Aβ drugs. In addition, emerging treatments targeting neuroinflammation in AD, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and receptor-interacting serine/threonine protein kinase 1 (RIPK1), that restore calcium dyshomeostasis and microglia physiological function in clearing Aβ plaques, respectively, will be deliberately discussed. Other novel pharmacotherapy strategies in treating AD, including disease-modifying agents (DMTs), repurposing of medications used to treat non-AD illnesses, and multi target-directed ligands (MTDLs) are also reviewed. These approaches open new doors to the development of AD therapy, especially combination therapy that can cater for several targets simultaneously, hence effectively slowing or stopping AD.

Item Type:	Article (Review)
Additional Information:	7497/80953
Uncontrolled Keywords:	Alzheimer, Alzheimer’s disease, amyloid, glutamate, neuro inflammation, pharmacotherapy tau protein
Subjects:	R Medicine > RC Internal medicine > RC321 Neuroscience. Biological psychiatry. Neuropsychiatry
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button):	Kulliyyah of Medicine > Department of Basic Medical Kulliyyah of Medicine
Depositing User:	Dr Wael Mohamed
Date Deposited:	26 Jun 2020 16:23
Last Modified:	19 Jan 2021 09:16
URI:	http://irep.iium.edu.my/id/eprint/80953

Actions (login required)

View Item